Diagnostics News and Research

RSS

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Through a complex analysis of protein interactions, researchers from IRB Barcelona and the Joint Programme IRB-BSC have discovered new molecular mechanisms that may be involved in the development of Alzheimer's disease.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

Accelr8 Technology Corporation announced its financial results for the first fiscal quarter ended October 31, 2010. Net sales revenues totaled $466,362; net income from operations was $49,974 with total net income of $67,250. For the previous quarter, net sales were $15,549 with a loss from operations of $(423,373) and a total net loss of $(411,981). Shareholders' equity totaled $4,985,682 at the current quarter's end, up from $4,909,778 at the end of the previous fiscal quarter.

17 Dec 2010

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Gen-Probe Incorporated announced today that the Company has acquired GTI Diagnostics, a privately held specialty diagnostics company focused on the transplantation, blood bank and specialty coagulation markets, for $53 million in cash.

17 Dec 2010

Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $150,000 Phase I Grant from the National Science Foundation (NSF). This initial round of funding from NSF will enable Akonni to assess the feasibility of developing a lab-on-a-film microarray device that can be manufactured in a reel-to-reel format.

16 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

BSGI/MBI provides additional information when conventional imaging is indeterminate in diagnosing breast cancer

Dr. Barbara Ward and others of Weinstein Imaging determined that Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional information when conventional imaging is indeterminate and greater confidence is required to improve diagnostic accuracy. The data from the retrospective study demonstrated that BSGI contributed significantly to patient management by detecting cancer in 7 of the 73 patients (9%), and was presented last week at the San Antonio Breast Cancer Symposium.

15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Marin announces new joint venture with Mt. Tam Spine Center and UCSF Neurosurgery

Marin General Hospital has announced a new joint venture that provides a single point of access in Marin for world-class, comprehensive multidisciplinary and cross-disciplinary treatment and management of spine and brain disorders and disease.

15 Dec 2010

Series of papers highlights challenges with moving African-developed drugs, technology forward

"Africa is struggling to turn local discoveries into drugs and other health care inventions," according to studies published in Science and BMC International Health and Human Rights, Nature News reports (Nordling, 12/12).

14 Dec 2010

We live longer, but not healthier

Increased life expectancy in the United States has not been accompanied by more years of perfect health, reveals new research published in the December issue of the Journal of Gerontology.

14 Dec 2010

Roche launches new xCELLigence System RTCA HT Instrument

The new xCELLigence System RTCA HT Instrument from Roche Diagnostics rounds out the company's portfolio in real-time cell analysis with a high-throughput product. The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications.

From Roche Sequencing and Life Science 14 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Silicon Biosystems' newly formed subsidiary to commercialize DEPArray technology platform

Silicon Biosystems, S.p.A., a provider of specialized molecular and cell biology technology, today announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company's DEPArray™ technology platform.

13 Dec 2010

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it has enrolled the first subject in its final phase of clinical studies for United States Food and Drug Administration ("FDA") approval of the Company's OraQuick® Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter ("OTC") market.

13 Dec 2010

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

13 Dec 2010

New DNA-based testing technology for tuberculosis treatment

The driving force behind the rapid tuberculosis test that received World Health Organization endorsement this week is Dr. David Alland, chief of the Division of Infectious Disease at UMDNJ-New Jersey Medical School.

13 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Caliper to acquire CRi for $20.0 million

Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. (CRi) for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications.

10 Dec 2010

Diagnostics News and Research

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Study: Biomarkers may aid in early diagnosis of breast cancer

Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Akonni receives $150,000 Phase I NSF grant to assess feasibility of developing lab-on-a-film microarray device

NextGen Healthcare announces partnership with Wills Eye for meaningful use

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

BSGI/MBI provides additional information when conventional imaging is indeterminate in diagnosing breast cancer

CTT, Bayer sign Research and License Option Agreement

Marin announces new joint venture with Mt. Tam Spine Center and UCSF Neurosurgery

Series of papers highlights challenges with moving African-developed drugs, technology forward

We live longer, but not healthier

Roche launches new xCELLigence System RTCA HT Instrument

Drug to reverse immunological decline in aging

Silicon Biosystems' newly formed subsidiary to commercialize DEPArray technology platform

OraSure commences enrollment in final study for FDA approval of OraQuick Rapid HIV-1/2 OTC test

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

New DNA-based testing technology for tuberculosis treatment

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Caliper to acquire CRi for $20.0 million

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News